Rheumatoid Arthritis Clinical Trial
— IDEAOfficial title:
A Multi-centre Randomised Double Blind Placebo Controlled Study Comparing Two Regimens of Combination Therapy in Early DMARD Naive Rheumatoid Arthritis.
Verified date | October 2019 |
Source | University of Leeds |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a placebo controlled randomised clinical trial.Patients attending Yorkshire Early Arthritis Clinics and diagnosed with rheumatoid arthritis with symptom duration of 3−12 months will be recruited. They will be randomised to blinded therapy with either methotrexate and intravenous corticosteroid at baseline, or methotrexate and intravenous infliximab according to the standard treatment regime. Patients will be followed regularly, and at each visit, if the patients are not in remission, they will be given an intramuscular injection of corticosteroid. After 26 weeks, all patients will be unblinded and those with an inadequate treatment response will be treated according to a dose escalation algorithm until they achieve remission. Those in remission will continue on blinded therapy and if 6 months of remission is achieved the intravenous agent (infliximab or placebo) will be withdrawn.
Status | Completed |
Enrollment | 112 |
Est. completion date | February 2011 |
Est. primary completion date | February 2011 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: - Men & Women 18-80 years of age. - Fulfil 1987 ACR criteria for RA. - Symptoms of > 3 months and < 12 months duration. - Men and women must use adequate birth control measures for the duration of the study and should continue such precautions for 6 months after receiving the last infusion or dose of methotrexate. - The patient must be able to adhere to the study visit schedule and other protocol requirements. - The patient must be capable of giving informed consent and the consent must be obtained prior to any screening procedures. - Must have a chest radiograph within 3 months prior to first treatment dose with no evidence of malignancy, infection or fibrosis. - Are considered eligible according to the tuberculosis (TB) eligibility assessment. - Active disease as defined by DAS > 2.4. - TNF therapy naïve. - DMARD therapy naïve. - Negative hepatitis B and C screening tests within 3 months prior to screening. Exclusion Criteria: - Women who are pregnant, nursing, or men or women planning pregnancy within 24 months after screening. - Use of any investigational (unlicensed) drug within 1 month prior to screening or within 5 half-lives of the investigational agent, whichever is longer. - Previous or current treatment with any other therapeutic agent targeted at reducing TNF. - Prior treatment with any DMARD. - Serious infections (such as pneumonia or pyelonephritis) in the previous 3 months. - Documented HIV infection. - Hepatitis- B or Hepatitis-C serology positive (must be checked within 3 months prior to screening). - Are considered ineligible according to the TB eligibility assessment. - Have or have had an opportunistic infection within 6 months prior to screening. - Significant haematological or biochemical abnormality. - Have current signs or symptoms of severe, progressive or uncontrolled renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, or cerebral disease. - Concomitant congestive heart failure, including medically controlled asymptomatic patients. - Presence of a transplanted organ (with the exception of a corneal transplant > 3 months prior to screening). - Malignancy within the past 5 years. - History of lymphoproliferative disease including lymphoma, or signs and symptoms suggestive of possible lymphoproliferative disease. - Known recent substance abuse (drug or alcohol). - Poor tolerability of venipuncture or lack of adequate venous access for required blood sampling during the study period. - Have a chest radiograph at screening that shows evidence of malignancy, infection, or any abnormalities suggestive of TB. - Have a positive Mantoux test or evidence of active TB infection, or recent close contact with an individual with active TB. - Previous oral, IM, IA or IV corticosteroids within 1 month prior to baseline. - Receiving treatment with anakinra. - Contra-indications to methotrexate, infliximab or steroids. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Chapel Allerton Hospital | Leeds | West Yorkshire |
Lead Sponsor | Collaborator |
---|---|
University of Leeds |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The primary endpoint is the change in Sharpe van der Heijde score | 50 Weeks | ||
Secondary | Number of patients having a major clinical response (DAS <1.6 for 6 months) | 78 Weeks | ||
Secondary | The change in Sharpe van der Heijde scores between baseline, 26 & 72 wk hand & feet x-rays | Week 72 | ||
Secondary | The number of patients in clinical remission (DAS <1.6) at 78 weeks | 78 Weeks | ||
Secondary | The number of patients in infliximab free remission (DAS <1.6) at 78 weeks | 78 Weeks | ||
Secondary | The number of patients in clinical remission (DAS <1.6) at 26 weeks | 26 Weeks | ||
Secondary | RA Quality of Life questionnaire | 78 Weeks | ||
Secondary | Health Assessment Questionnaire | 78 Weeks | ||
Secondary | Immunogenetic studies to predict long-term immune response | 78 Weeks | ||
Secondary | Immune phenotyping (flow cytometry) and assessment of immune effector & regulatory functions | 78 Weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04226131 -
MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics
|
N/A | |
Completed |
NCT04171414 -
A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT02833350 -
Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)
|
Phase 2 | |
Completed |
NCT04255134 -
Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)
|
Phase 4 | |
Recruiting |
NCT05615246 -
Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
|
||
Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
Completed |
NCT03514355 -
MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms
|
N/A | |
Recruiting |
NCT06005220 -
SBD121, a Synbiotic Medical Food for RA Management
|
N/A | |
Recruiting |
NCT05451615 -
Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT05054920 -
Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT02037737 -
Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting
|
N/A | |
Recruiting |
NCT04079374 -
Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel
|
Phase 3 | |
Completed |
NCT02504268 -
Effects of Abatacept in Patients With Early Rheumatoid Arthritis
|
Phase 3 | |
Recruiting |
NCT05496855 -
Remote Care in People With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Recruiting |
NCT06103773 -
A Study of Single and Multiple Oral Doses of TollB-001
|
Phase 1 | |
Recruiting |
NCT06031415 -
Study of GS-0272 in Participants With Rheumatoid Arthritis
|
Phase 1 | |
Completed |
NCT05999266 -
The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
|
||
Recruiting |
NCT05302934 -
Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
|
||
Recruiting |
NCT04169100 -
Novel Form of Acquired Long QT Syndrome
|
Phase 4 |